Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HLN 
Haleon plc (HLN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/21/2025: HLN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.64
1 Year Target Price $11.64
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.37% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/21/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 42.12B USD | Price to earnings Ratio 20.91 | 1Y Target Price 11.64 |
Price to earnings Ratio 20.91 | 1Y Target Price 11.64 | ||
Volume (30-day avg) 5 | Beta 0.23 | 52 Weeks Range 8.70 - 11.35 | Updated Date 10/21/2025 |
52 Weeks Range 8.70 - 11.35 | Updated Date 10/21/2025 | ||
Dividends yield (FY) 0.72% | Basic EPS (TTM) 0.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 13.81% | Operating Margin (TTM) 22.21% |
Management Effectiveness
Return on Assets (TTM) 4.61% | Return on Equity (TTM) 9.38% |
Valuation
Trailing PE 20.91 | Forward PE 16.53 | Enterprise Value 50061749542 | Price to Sales(TTM) 3.82 |
Enterprise Value 50061749542 | Price to Sales(TTM) 3.82 | ||
Enterprise Value to Revenue 3.37 | Enterprise Value to EBITDA 13.69 | Shares Outstanding 4452921092 | Shares Floating 8991532200 |
Shares Outstanding 4452921092 | Shares Floating 8991532200 | ||
Percent Insiders 0.02 | Percent Institutions 12.91 |
Upturn AI SWOT
Haleon plc
Company Overview
History and Background
Haleon plc was formed in July 2022 as a spin-off from GlaxoSmithKline (GSK). It focuses exclusively on consumer healthcare products, building on GSK's existing portfolio. Its roots trace back to the consumer healthcare businesses of GSK and Pfizer, which were combined prior to the spin-off.
Core Business Areas
- Oral Health: Includes toothpaste, toothbrushes, and mouthwash products. Brands include Sensodyne, Parodontax, and Polident.
- Pain Relief: Includes over-the-counter pain relief medications. Brands include Panadol, Advil, and Voltaren.
- Vitamins, Minerals and Supplements (VMS): Includes vitamins, minerals and supplements. Brands include Centrum and Emergen-C.
- Respiratory Health: Includes over-the-counter cold and flu remedies. Brands include Theraflu and Robitussin.
- Digestive Health and Other: Includes products for digestive issues and other consumer health needs. Brands include TUMS.
Leadership and Structure
Brian McNamara is the CEO. The company has a board of directors and is structured into global business units focused on specific product categories.
Top Products and Market Share
Key Offerings
- Sensodyne: A leading toothpaste brand for sensitive teeth, with significant market share globally. Competitors include Colgate Sensitive and Crest Pro-Health. Revenue data not explicitly available publicly but represents a significant portion of Haleon's oral health sales.
- Panadol: A widely used pain reliever containing paracetamol/acetaminophen. Competitors include Tylenol (JNJ) and generic brands. Market share varies by region but is generally significant in Asia and parts of Europe. Revenue data not explicitly available publicly but represents a significant portion of Haleon's pain relief sales.
- Advil: An over-the-counter pain reliever containing ibuprofen. Advil is in competition with generic brands and is widely used globally. Revenue data not explicitly available publicly but represents a significant portion of Haleon's pain relief sales.
- Centrum: A leading multivitamin brand for adults. Competitors include One A Day (BAYRY). Market share varies by region, but is a leading brand worldwide. Revenue data not explicitly available publicly but represents a significant portion of Haleon's VMS sales.
Market Dynamics
Industry Overview
The consumer healthcare industry is characterized by increasing demand for self-care solutions, aging populations, and growing awareness of preventive healthcare. It's a competitive market with strong brand loyalty.
Positioning
Haleon plc is positioned as a global leader in consumer healthcare, focusing on established brands and innovation. Its competitive advantage lies in its portfolio of well-known brands, strong distribution network, and R&D capabilities.
Total Addressable Market (TAM)
The global consumer healthcare market is estimated to be hundreds of billions of dollars. Haleon is positioned to capture a significant share through its diverse product portfolio and global presence.
Upturn SWOT Analysis
Strengths
- Strong Brand Portfolio
- Global Presence and Distribution Network
- R&D Capabilities
- Established Market Position
- High Brand Recognition
Weaknesses
- High Debt Levels (related to spin-off)
- Exposure to Currency Fluctuations
- Reliance on Key Brands
- Potential for Generic Competition
- Limited Pricing Power in Some Markets
Opportunities
- Expanding into Emerging Markets
- Developing Innovative Products
- Acquiring Complementary Businesses
- Increasing Focus on Digital Marketing
- Capitalizing on Growing Self-Care Trend
Threats
- Intense Competition
- Changing Consumer Preferences
- Stringent Regulatory Environment
- Economic Downturns
- Supply Chain Disruptions
Competitors and Market Share
Key Competitors
- JNJ
- BAYRY
- PFE
- MRK
Competitive Landscape
Haleon possesses a substantial competitive edge due to its established brand portfolio and distribution network. Challenges include intense competition from other major players and the need to continually innovate and adapt to changing consumer preferences.
Major Acquisitions
Dr. Kurt Wolff
- Year: 2021
- Acquisition Price (USD millions): 576
- Strategic Rationale: The strategic rationale was to expand its presence in the dermatology market.
Growth Trajectory and Initiatives
Historical Growth: Haleon's historical growth is based on the performance of the combined consumer healthcare businesses of GSK and Pfizer prior to the spin-off. More recent data reflects Haleon's performance as an independent entity.
Future Projections: Analyst estimates suggest continued growth in line with the overall consumer healthcare market. Specific revenue and earnings growth projections are available from financial analysts.
Recent Initiatives: Recent initiatives include expansion into new markets, development of new products, and investments in digital marketing and e-commerce.
Summary
Haleon is a strong player in the consumer healthcare market with a portfolio of well-known brands and a global presence. While the company carries a high debt load and faces competition, it has growth opportunities through expansion and innovation. Key things to watch are currency fluctuations, competition, and supply chain risks. Their solid brand equity and distribution network provide a good foundation for success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Haleon plc Investor Relations
- Company Financial Reports
- Market Research Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Haleon plc
Exchange NYSE | Headquaters - | ||
IPO Launch date 2022-07-22 | CEO & Executive Director Mr. Brian James McNamara | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 24561 | Website https://www.haleon.com |
Full time employees 24561 | Website https://www.haleon.com | ||
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.